CEBPA anticorps

N° du produit ABIN2664083

Cet anticorps anti-CEBPA Monoclonal Souris (Clone 16C12B70) (ABIN2664083) détecte spécifiquement CEBPA dans FACS et IF. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour CEBPA anticorps (ABIN2664083)

Antigène: CEBPA (CCAAT/enhancer Binding Protein (C/EBP), alpha (CEBPA))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CEBPA est non-conjugé

Application: Flow Cytometry (FACS), Immunofluorescence (IF)

Clone: 16C12B70

Détail du produit anti-CEBPA anticorps

Réactivité croisée: Souris

Réactivité croisée (Details): weakly cross-reacts with mouse

Purification: The antibody was purified by affinity chromatography.

Isotype: IgG2a kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur CEBPA

Antigène: CEBPA (CCAAT/enhancer Binding Protein (C/EBP), alpha (CEBPA))

Autre désignation: C/EBPalpha

Sujet: The CCAAT-enhancer binding proteins (C/EBP) are members of the basic region/leucine zipper (bZIP) transcription factors, that bind to the consensus CCAAT sequence in DNA. C/EBPα is expressed in two isoforms: p42 and p30 by ultilizing different translational start codons. The C/EBPα p30 isoform has little to no transactivating activity and acts as an inhibitor. C/EBPα regulates expression of various myeloid-specific genes and is required for myeloid differentiation. C/EBPα has been found to play a key role in adipogenesis, since inhibition of C/EBPα blocks adipocyte differentiation. C/EBPα also regulates cell cycle progression through interactions with cyclin-dependent kinases (CDK) and by inducing the expression of CDK inhibitor p21. Mutations in the C/EBPα gene are associated with the development of acute myeloid leukemia.

Pathways: Brown Fat Cell Differentiation, Positive Regulation of fat Cell Differentiation